SeekingAlpha · Sep 15, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow
2026-09-15. The following slide deck was published by Rigel Pharmaceuticals, Inc.
RI
NASDAQ · RIGL
Rigel Pharmaceuticals, Inc.
Healthcare · Biotechnology
$44.36
Up+$0.36 (+0.80%)
Updated Sep 16, 2026, 2:08 PM
SID Score
6.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 751.68M
- P/E ratio
- 6.71
- Dividend yield
- 0.00%
- 52-week range
- $24.95 – $52.24
- Volume
- 269.89K
- Avg. volume
- 631.51K
Price performance
RIGL price history
1M range · 20 trading sessions · Daily adjusted prices
RIGL closed at $44.36 after 20 trading sessions, up 1.70% for the selected period.
- Last close
- $44.36
- Period change
- +1.70%
- Period low
- $43.62
- Period high
- $49.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $45.14 | $46.255 | $44.22 | $44.36 | 269.89K |
| Sep 14, 2026 | $47.32 | $47.53 | $44.96 | $45.35 | 335.81K |
| Sep 11, 2026 | $47.84 | $47.86 | $47.00 | $47.24 | 187.18K |
| Sep 10, 2026 | $46.69 | $47.35 | $46.2838 | $47.28 | 131.33K |
| Sep 9, 2026 | $46.85 | $47.8799 | $46.775 | $47.22 | 177.15K |
| Sep 8, 2026 | $48.09 | $48.11 | $46.61 | $47.37 | 248.4K |
| Sep 4, 2026 | $48.04 | $48.87 | $47.77 | $48.67 | 104.97K |
| Sep 3, 2026 | $49.51 | $49.90 | $48.09 | $48.50 | 190.39K |
| Sep 2, 2026 | $48.00 | $49.70 | $47.73 | $49.42 | 184.7K |
| Sep 1, 2026 | $46.15 | $47.85 | $46.15 | $47.50 | 205.51K |
| Aug 31, 2026 | $46.04 | $46.59 | $45.31 | $46.18 | 243.09K |
| Aug 28, 2026 | $46.46 | $46.79 | $45.6805 | $46.48 | 246.13K |
| Aug 27, 2026 | $46.29 | $47.00 | $45.605 | $46.86 | 210.03K |
| Aug 26, 2026 | $46.34 | $47.09 | $45.365 | $46.48 | 232.25K |
| Aug 25, 2026 | $45.48 | $47.46 | $45.14 | $46.75 | 373.97K |
| Aug 24, 2026 | $45.63 | $46.21 | $44.505 | $45.11 | 542.01K |
| Aug 21, 2026 | $45.74 | $46.4925 | $45.00 | $45.89 | 322.09K |
| Aug 20, 2026 | $46.24 | $47.34 | $44.795 | $45.25 | 417.41K |
| Aug 19, 2026 | $44.02 | $47.25 | $44.00 | $46.96 | 515.83K |
| Aug 18, 2026 | $42.31 | $43.71 | $41.3701 | $43.62 | 267.32K |
Latest RIGL news
The latest Smart Investors Daily articles mentioning RIGL.
Stock researchCompany · Overview
RIGL research
Overview
Company profile and research snapshot.
Company profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $40.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Piper Sandler | Neutral | — |
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 2, 2026 | HC Wainwright & Co. | Buy | — |
| May 27, 2026 | HC Wainwright & Co. | Buy | — |
| May 22, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
Generated Sep 16, 2026, 1:07 PM
Why Is RIGL Down Today?
Rigel Pharmaceuticals (RIGL) declined 2.18% today despite continued investor engagement through major healthcare conferences. The modest pullback appears disconnected from company-specific catalysts, suggesting broader market headwinds or profit-taking rather than fundamental deterioration.
Bottom line: Rigel's modest decline today appears driven by general market sentiment rather than company-specific deterioration, as evidenced by continued conference presentations and growing tailwinds in the MDS market. Investors should monitor upcoming clinical data, partnership announcements, and regulatory developments as key catalysts that could justify the company's valuation relative to the expanding therapeutic opportunities ahead.
Yahoo · Sep 15, 2026
Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight
Recently published Myelodysplastic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, myelodysplastic syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
SeekingAlpha · Sep 15, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow
2026-09-15. The following slide deck was published by Rigel Pharmaceuticals, Inc.
Benzinga · Sep 4, 2026
EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K
A large exercise of company stock options by Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals (NASDAQ:RIGL) was disclosed in a new SEC filing on September 3, as part of an insider exercise. What
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
